p53
Can Karyopharm's Blood Cancer Drug Xpovio Be an Option in KRAS-Mutant, TP53 Wild-Type Lung Cancer?
Premium
In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than G12C.
Lamassu Biotech Garners FDA Clearance to Start Phase I MDM2 Therapy Trial in p53-Wildtype Tumors
The firm previously received a $2.05 million NIH grant to support development of SA53-OS in p53-wildtype sarcomas.
A Wistar Institute team found that two hypomorphic p53 variants in separate domains of that gene generate a shared gene expression signature in certain African populations.
Elicio Receives $2.8M Grant for Cancer Vaccine Development
The company will use the grant to develop vaccines targeting BRAF V600E and p53 hotspot mutations in solid tumors.
Aileron Therapeutics Pivots to Breast Cancer Development for ALRN-6924 After NSCLC Miss
Aileron believes an improved protocol for its Phase Ib breast cancer trial can show benefits for its chemoprotective drug after it failed to beat placebo in NSCLC.
Jul 13, 2022
Aug 14, 2020
Jul 13, 2020